[ad_1]
Henry Schein, a provider of healthcare products and services to office-based dental and medical practitioners and headquartered in Melville, has named Frederick Lowery as its new CEO. Lowery, who takes the reins March 2, succeeds Stanley Bergman, who will step down as CEO after 35 years and continue to serve as chairman of the board, helping to ensure a smooth leadership transition.
Lowery brings more than 20 years of healthcare industry experience to Henry Schein, with expertise in scaling complex businesses to achieve long-term growth. Most recently, he served as executive vice president and president of Laboratory Products and BioProduction at Thermo Fisher Scientific.
His background in expanding distribution networks and building businesses around proprietary products aligns with Henry Schein’s business model and positions him to support the company’s ongoing growth and execution of its long-term strategic initiatives, according to the company.
“I am honored to join Henry Schein at such a pivotal moment,” Lowery said in a news release about leading the company.
“This is an organization with immense potential to impact clinicians and patients, given its remarkable reputation for innovation, customer service and partnership,” he added. “I look forward to working with ‘Team Schein’ to build on the strong foundation established by Stan while accelerating value creation.”
Bergman said in the news release that he is “very pleased to welcome Fred to Henry Schein. Beyond his extensive operational experience, he brings a leadership philosophy that reflects the values that have long defined our company.
“Fred understands the critical role we play in supporting dental and medical practitioners, and he is exceptionally well equipped to lead Henry Schein into its next phase of growth,” he added.
“On behalf of the board, I would like to thank Stan for his exceptional leadership and invaluable contributions over more than three decades,” Phil Laskawy, lead director and chair of the Nominating and Governance Committee at Henry Schein, said in the news release.
“After a comprehensive search process, we are confident that Fred is the right successor to honor Henry Schein’s proud heritage,” Laskawy added. “With extensive commercial, logistics and manufacturing expertise, and a focus on customer satisfaction, he has the combination of experience and capabilities necessary to accelerate growth and value creation.”
That sentiment was shared by KKR, which completed a $250 million investment in Henry Schein in May.
“We are excited about our strategic partnership with Henry Schein and look forward to supporting the next chapter of the company’s journey under Fred’s leadership,” Max Lin, board member and vice chair of the Nominating and Governance Committee at Henry Schein and partner at KKR, said in the news release.
“We believe Fred brings a unique combination of healthcare distribution experience, operational best practices and accountable leadership that will accelerate our strategic initiatives and further differentiate Henry Schein as a world-class business,” Lin said.
Prior to joining Thermo Fisher, Lowery served in leadership roles for Maytag Corporation and General Motors. He holds a master’s degree in manufacturing management from Kettering University (formerly General Motors Institute of Engineering and Management) and a bachelor’s degree in mechanical engineering from Tennessee Technological University.
[ad_2]
Adina Genn
Source link


